



Bayer AG  
Communications  
51368 Leverkusen  
Germany  
Tel. +49 214 30-1  
[media.bayer.com](http://media.bayer.com)

## News Release

---

Initiative offers financial support for novel approaches and enabling technologies in crop research:

### **Bayer opens application window for Grants4Traits™ and Grants4Biologicals™**

---

**Monheim, September 11, 2019** – Bayer announced today that it has opened the application window for its Grants4 initiative. First introduced in 2015, the initiative offers researchers financial and scientific support to develop ideas for novel solutions, including gene editing targets, that will help to achieve higher yield and safety in crops as they face increasing pressure from weeds, insects, diseases, and unfavorable climate conditions. Deadline for submissions is November 15, 2019.

“Our research and development platforms are bolstered by our ‘open innovation’ model,” said Phil Taylor, Corporate Innovation and R&D Business Partner for the Crop Science division. “Grants4Traits exemplifies that approach, providing outside researchers the resources to create solutions to control existing crop threats and get ahead of emerging ones.”

“At Bayer, we have a multidisciplinary research and development team focusing solely on biological solutions – but we can’t do it alone,” said Benoit Hartmann, Head of Biologicals at Crop Science. “We also count on strengthening our crop protection portfolio by forming collaborations with innovative partners, which is one reason why we created Grants4Biologicals.”

Bayer is looking for novel approaches that could lead to innovative solutions in five categories: Yield enhancement, Pest control, Disease control, Weed control and Enabling technologies.

There are two types of grants that will be allocated by Bayer, depending on the approach/trait described, the scientific data provided and the maturity of the proposal. Support grants from 2,000 Euros to 10,000 Euros are for proposals that are at a very early stage of discovery, and focus grants from 10,000 Euros to 50,000 Euros are for more advanced proposals to support promising research towards fully validated solutions. The size of the individual grant will depend on the target specifics and the state of development and validation.

Full details on the programs' sought-after solutions, application process and submission rules are available at <https://grants4traits.bayer.com/home> and <https://www.grants4biologicals.bayer.com/home/>.

Bayer offers a number of funding and partnering innovation opportunities across its three divisions of Pharmaceuticals, Crop Science, and Consumer Health. Information on these programs may be found at <https://innovate.bayer.com>.

### **About Bayer**

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to [www.bayer.com](http://www.bayer.com).

Contact:

**Holger Elfes, phone +49 2173 38-3270**

Email: [holger.elfes@bayer.com](mailto:holger.elfes@bayer.com)

R&D Communications Manager Crop Science

**John Combest, phone +1 314 6946397**

Email: [john.combest@bayer.com](mailto:john.combest@bayer.com)

Find more information at [www.bayer.com](http://www.bayer.com).

hel (2019-0243E)

**Forward-Looking Statements**

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at [www.bayer.com](http://www.bayer.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.